Maria Alexandrovna Shkolnikova

Maria Alexandrovna Shkolnikova

Auto-generated profile, based on publicly available information

Maria Alexandrovna Shkolnikova

Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2006 in Circulation
Verified
Journal Article
Closed access
PDF file
Peter J. SchwartzPeter J. Schwartz
Peter J. Schwartz
CSCarla Spazzolini
Carla Spazzolini
Lia CrottiLia Crotti
Lia Crotti
JBJørn Bathen
Jørn Bathen
JAJan P. Amlie
Jan P. Amlie
IDIsabelle Denjoy
Isabelle Denjoy
Background— Data on the Jervell and Lange-Nielsen syndrome (J-LN), the long-QT syndrome (LQTS) variant associated with deafness and caused by homozygous or compound heterozygous mutations on the KCNQ1 or on the KCNE1 genes encoding the I Ks current, are still based largely on case reports. Methods and Results— We analyzed data from 186 J-LN patients obtained from the literature (31%) and from individual physicians (69%). Most patients (86%) had cardiac events, and 50% were already symptomatic by age 3. Their QTc was markedly prolonged (557±65 ms). Most of the arrhythmic events (95%) were triggered by emotions or exercise. Females are at lower risk for cardiac arrest and sudden death (CA/SD) (hazard ratio, 0.54; 95% CI, 0.34 to 0.88; P =0.01). A QTc >550 ms and history of syncope during the first year of life are independent predictors of subsequent CA/SD. Most mutations (90.5%) are on the KCNQ1 gene; mutations on the KCNE1 gene are associated with a more benign course. β-Blockers have only partial efficacy; 51% of the patients had events despite therapy and 27% had CA/SD. Conclusions— J-LN syndrome is a most severe variant of LQTS, with a very early onset and major QTc prolongation, and in which β-blockers have limited efficacy. Subgroups at relatively lower risk for CA/SD are identifiable and include females, patients with a QTc ≤550 ms, those without events in the first year of life, and those with mutations on KCNE1 . Early therapy with implanted cardioverter/defibrillators must be considered.

1 June 2015 in Circulation
Verified
Journal Article
Closed access
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
VDVeronica Dusi
Veronica Dusi
CSCarla Spazzolini
Carla Spazzolini
JBJ. Martijn Bos
J. Martijn Bos
DADominic J. Abrams
Dominic J. Abrams
Peter J. SchwartzPeter J. Schwartz
Peter J. Schwartz
Background—: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-threatening arrhythmias whenever sympathetic activity increases. β-Βlockers are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often cause multiple shocks. Preliminary results with flecainide appear encouraging. We proposed left cardiac sympathetic denervation (LCSD) as useful additional therapy, but evidence remains anecdotal. Methods and Results—: We report 63 patients with CPVT who underwent LCSD as secondary (n=54) or primary (n=9) prevention. The median post-LCSD follow-up was 37 months. The 9 asymptomatic patients remained free of major cardiac events. Of the 54 patients with prior major cardiac events either on (n=38) or off (n=16) optimal medical therapy, 13 (24%) had at least 1 recurrence: 0 patients had an aborted cardiac arrest, 2 patients had syncope only, 10 patients had ≥1 appropriate ICD discharges, and 1 patient died suddenly. The 1- and 2-year cumulative event-free survival rates were 87% and 81%. The percentage of patients with major cardiac events despite optimal medical therapy (n=38) was reduced from 100% to 32% ( P <0.001) after LCSD, and among 29 patients with a presurgical ICD, the rate of shocks dropped by 93% from 3.6 to 0.6 shocks per person per year ( P <0.001). Patients with an incomplete LCSD (n=7) were more likely to experience major cardiac events after LCSD (71% versus 17%; P <0.01) than those with a complete LCSD. Conclusions—: LCSD is an effective antifibrillatory intervention for patients with CPVT. Whenever syncope occurs despite optimal medical therapy, LCSD could be considered the next step rather than an ICD and could complement ICDs in patients with recurrent shocks.

19 February 1999 in Circulation Research
Verified
Journal Article
Closed access
PDF file
NNNathalie Neyroud
Nathalie Neyroud
PRPascale Richard
Pascale Richard
NVNicolas Vignier
Nicolas Vignier
CDClaire Donger
Claire Donger
IDIsabelle Denjoy
Isabelle Denjoy
PGPascale Guicheney
Pascale Guicheney
—The voltage-gated K + channel KVLQT1 is essential for the repolarization phase of the cardiac action potential and for K + homeostasis in the inner ear. Mutations in the human KCNQ1 gene encoding the α subunit of the KVLQT1 channel cause the long-QT syndrome (LQTS). The autosomal dominant form of this cardiac disease, the Romano-Ward syndrome, is characterized by a prolongation of the QT interval, ventricular arrhythmias, and sudden death. The autosomal recessive form, the Jervell and Lange-Nielsen syndrome, also includes bilateral deafness. In the present study, we report the entire genomic structure of KCNQ1 , which consists of 19 exons spanning 400 kb on chromosome 11p15.5. We describe the sequences of exon-intron boundaries and oligonucleotide primers that allow polymerase chain reaction (PCR) amplification of exons from genomic DNA. Two new (CA) n repeat microsatellites were found in introns 10 and 14. The present study provides helpful tools for the linkage analysis and mutation screening of the complete KCNQ1 gene. By use of these tools, five novel mutations were identified in LQTS patients by PCR–single-strand conformational polymorphism (SSCP) analysis in the C-terminal part of KCNQ1 : two missense mutations, a 20-bp and 1-bp deletions, and a 1-bp insertion. Such mutations in the C-terminal domain of the gene may be more frequent than previously expected, because this region has not been analyzed so far. This could explain the low percentage of mutations found in large LQTS cohorts.

13 August 2009 in BMC Public Health
Verified
Journal Article
Open access
PDF file
MSMaria Shkolnikova
Maria Shkolnikova
SSSvetlana Shalnova
Svetlana Shalnova
VSVladimir M Shkolnikov
Vladimir M Shkolnikov
VMVictoria A Metelskaya
Victoria A Metelskaya
ADAlexander Deev
Alexander Deev
JVJames W Vaupel
James W Vaupel
Prior research has revealed large differences in health and mortality across countries, socioeconomic groups, and individuals. Russia experiences one of the world's highest levels of all-cause and cardiovascular mortality, great mortality differences within the population, and a heavy burden of ill health. Psychological stress has been suggested as a likely explanation of health loss and premature death in Russia and Eastern Europe. However, physiological mechanisms connecting stress with health in Russia remain unclear since existing epidemiological data are scarce and limited to conventional risk factors.

26 March 2014 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
AOA. Oksuzyan
A. Oksuzyan
MSM. Shkolnikova
M. Shkolnikova
JVJ. W. Vaupel
J. W. Vaupel
KCK. Christensen
K. Christensen
VSV. M. Shkolnikov
V. M. Shkolnikov

10 September 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Peter J. SchwartzPeter J. Schwartz
Peter J. Schwartz
CMCristina Moreno
Cristina Moreno
MKMaria-Christina Kotta
Maria-Christina Kotta
MPMatteo Pedrazzini
Matteo Pedrazzini
Lia CrottiLia Crotti
Lia Crotti
PVPaul G.A. Volders
Paul G.A. Volders
Mutation type, location, dominant-negative I Ks reduction, and possibly loss of cyclic adenosine monophosphate (cAMP)-dependent I Ks stimulation via protein kinase A (PKA) influence the clinical severity of long QT syndrome type 1 (LQT1). Given the malignancy of KCNQ1-p.A341V, we assessed whether mutations neighbouring p.A341V in the S6 channel segment could also increase arrhythmic risk. Clinical and genetic data were obtained from 1316 LQT1 patients [450 families, 166 unique KCNQ1 mutations, including 277 p.A341V-positive subjects, 139 patients with p.A341-neighbouring mutations (91 missense, 48 non-missense), and 900 other LQT1 subjects]. A first cardiac event represented the primary endpoint. S6 segment missense variant characteristics, particularly cAMP stimulation responses, were analysed by cellular electrophysiology. p.A341-neighbouring mutation carriers had a QTc shorter than p.A341V carriers (477 ± 33 vs. 490 ± 44 ms) but longer than the remaining LQT1 patient population (467 ± 41 ms) (P < 0.05 for both). Similarly, the frequency of symptomatic subjects in the p.A341-neighbouring subgroup was intermediate between the other two groups (43% vs. 73% vs. 20%; P < 0.001). These differences in clinical severity can be explained, for p.A341V vs. p.A341-neighbouring mutations, by the p.A341V-specific impairment of I Ks regulation. The differences between the p.A341-neighbouring subgroup and the rest of LQT1 mutations may be explained by the functional importance of the S6 segment for channel activation. KCNQ1 S6 segment mutations surrounding p.A341 increase arrhythmic risk. p.A341V-specific loss of PKA-dependent I Ks enhancement correlates with its phenotypic severity. Cellular studies providing further insights into I Ks-channel regulation and knowledge of structure-function relationships could improve risk stratification. These findings impact on clinical management. Upper panel: Topology of KCNQ1 missense and non-missense mutations identified in all studied long QT syndrome type 1 patients (n = 1316), according to their amino acid position along the KCNQ1 channel. Location of p.A341V and p.A341-neighbouring mutations in the KCNQ1-S6 segment is highlighted in red and blue, respectively. Exemplary I Ks traces for p.A341V (red) and p.A341V-neighbouring mutation (blue), with and without cyclic adenosine monophosphate/okadaic acid are depicted on the left. Left lower panel: structural image of the pore of the I Ks channel. Amino acid position A341 is indicated in red and the A341-neighbouring amino acids in blue. Right lower panel: Cumulative event-free survival of patients with p.A341V (red; n = 269), p.A341-neighbouring mutations (blue; n = 91), and all other KCNQ1-missense mutations located outside the S6 region (black; n = 611).